<DOC>
	<DOCNO>NCT02646748</DOCNO>
	<brief_summary>This open-label , Phase 1b , 3 Part ( Part 1a , Part 1b Part 2 ) , multi-center study . Part 1a utilizes 3+3 design evaluate pembrolizumab INCB combination advance solid tumor . Group A evaluate JAK inhibitor JAK1 selectivity itacitinib ( INCB039110 ) combination pembrolizumab ( MK-3475 ) Group B evaluate PI3K-delta inhibitor ( INCB050465 ) combination pembrolizumab determine maximum tolerate dose ( MTD ) PAD recommend dose Part 1b safety expansion combination . Once recommend dose identified Part 1a , subject select solid tumor type enrol safety expansion cohort base upon prior treatment history PD-1 pathway-targeted agent ( Part 1b ) combination . Part 2 utilizes Simon 2-Stage design evaluate INCB050465 combination pembrolizumab patient small cell lung cancer ( SCLC ) .</brief_summary>
	<brief_title>Pembrolizumab Combined With Itacitinib ( INCB039110 ) and/or Pembrolizumab Combined With INCB050465 Advanced Solid Tumors</brief_title>
	<detailed_description>This open-label , Phase 1b , 3 Part ( Part 1a , Part 1b , Part 2 ) , multi-center study . Part 1a utilizes 3+3 design evaluate pembrolizumab INCB combination advance solid tumor . Group A evaluate JAK inhibitor JAK1 selectivity itacitinib ( INCB039110 ) combination pembrolizumab ( MK-3475 ) Group B evaluate PI3K-delta inhibitor ( INCB050465 ) combination pembrolizumab determine maximum tolerate dose ( MTD ) PAD recommend dose Part 1b safety expansion combination . Once recommend dose identified Part 1a , subject endometrial cancer , gastric cancer , melanoma , microsatellite unstable ( MSI ) colorectal cancer MMR-deficient tumor , non-small cell lung cancer , renal cell carcinoma , head neck squamous cell carcinoma , triple negative breast cancer , pancreatic ductal carcinoma , transitional cell carcinoma genitourinary tract enrol safety expansion cohort base upon prior treatment history PD-1 pathway-targeted agent ( Part 1b ) combination . Part 2 utilizes Simon 2-Stage design evaluate INCB050465 combination pembrolizumab patient small cell lung cancer ( SCLC ) .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Carcinoma , Squamous Cell</mesh_term>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<mesh_term>Small Cell Lung Carcinoma</mesh_term>
	<mesh_term>Endometrial Neoplasms</mesh_term>
	<mesh_term>Triple Negative Breast Neoplasms</mesh_term>
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Transitional Cell</mesh_term>
	<mesh_term>Pembrolizumab</mesh_term>
	<criteria>Male female , age 18 year old . Willingness provide write informed consent study . Has baseline tumor biopsy specimen available willingness undergo pretreatment tumor biopsy obtain specimen . Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 . For Part 1a : Subjects histologically cytologically confirm advanced metastatic solid tumor fail prior standard therapy ( include subject refusal intolerance ) . For Part 1b : Subjects histologically cytologically confirm advanced metastatic endometrial cancer , gastric cancer , melanoma , microsatellite unstable ( MSI ) colorectal cancer MMRdeficient tumor , nonsmall cell lung cancer , renal cell carcinoma , head neck squamous cell carcinoma , triple negative breast cancer , pancreatic ductal carcinoma , transitional cell carcinoma genitourinary tract disease progression available therapy advance metastatic disease know confer clinical benefit , intolerant treatment , refuse standard treatment . For Part 1b : Must document confirmed disease progression prior PD1 pathway target agent must PD1 pathwaytargeted treatment na√Øve . For Part 2 : Subjects histologically cytologically confirm advanced metastatic SCLC . Must previous treatment antibody modulate Tcell function checkpoint pathway . Must disease progression platinumbased chemotherapy must intolerant refuse standard treatment . Must receive 2 line prior therapy . Laboratory parameter within protocoldefined range . Receipt anticancer medication investigational drug within define interval first administration study drug . Received immunesuppressive base treatment reason within 14 day prior first dose study treatment . Has recover toxic effect prior therapy &lt; Grade 1 . Active inactive autoimmune process . Has receive live vaccine within 30 day plan start study therapy . Active infection require systemic therapy .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Advanced</keyword>
</DOC>